Conference Correspondent

The initial results of a phase 1 study suggest that combination therapy with ivosidenib or enasidenib plus standard induction chemotherapy is well-tolerated and effective in newly diagnosed patients with IDH-mutated (mIDH), relapsed/refractory acute myeloid leukemia (AML).

In this analysis, the hedgehog pathway inhibitor sonidegib plus azacitidine combination therapy showed encouraging antileukemia activity in terms of high rate of disease stabilization, particularly in the relapsed/refractory acute myeloid leukemia patient population.

The results of the Radius-X expanded treatment protocol showed a safety profile that was consistent with that previously described in patients with FLT3 mutation–positive, newly diagnosed acute myeloid leukemia (AML).

Ivosidenib monotherapy is well-tolerated and produced durable remissions in high-risk patients with relapsed/refractory acute myeloid leukemia (AML).

Interim results of an ongoing phase 1 study showed that the addition of the selective FLT3 inhibitor quizartinib to azacitidine or low-dose cytarabine produced high overall response rates in patients with FLT3-ITD–mutated myeloid leukemias.

The preliminary results of a multicenter phase 1b dose-escalation study evaluated the safety, tolerability, and efficacy of 2 novel venetoclax-based combination therapies, in combination with the MEK inhibitor cobimetinib or the MDM2 inhibitor idasanutlin, in relapsed/refractory (R/R) acute myeloid leukemia (AML).

MMY1001 is an open-label phase 1b study of daratumumab in combination with carfilzomib, lenalidomide, and dexamethasone in newly diagnosed patients with multiple myeloma.

The combination of elotuzumab, bortezomib, lenalidomide, and dexamethasone is effective in patients with newly diagnosed multiple myeloma (MM).

A phase 1b study showed that isatuximab is clinically active in patients with relapsed/refractory multiple myeloma.

The combination of bendamustine and pomalidomide with dexamethasone shows promise in patients with relapsed/refractory multiple myeloma (RRMM).